U.S. markets closed

Is Calumet Specialty Products Partners (CLMT) Stock a Solid Choice Right Now?

Zacks Equity Research

One stock that might be an intriguing choice for investors right now is Calumet Specialty Products Partners, L.P. CLMT. This is because this security in the Oil and Gas - Refining and Marketing - Master Limited Partnerships space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Oil and Gas - Refining and Marketing - Master Limited Partnerships space as it currently has a Zacks Industry Rank of 52 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Calumet Specialty Products Partners is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.



In fact, over the past month, current quarter estimates have narrowed from a loss of 50 cents per share to a loss of 39 cents per share, while current year estimates have narrowed from a loss of $1.23 per share to a loss of $1.09 per share. This has helped CLMT to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Calumet Specialty Products Partners. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Calumet Specialty Products Partners, L.P. (CLMT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research